You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 6,406,713


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,406,713
Title: Methods of preparing low-toxicity drug-lipid complexes
Abstract:Methods and compositions are described for nonliposomal lipid complexes in association with toxic hydrophobic drugs such as the polyene antibiotic amphotericin B. Lipid compositions are preferably a combination of the phospholipids dimyristoylphosphatidylcholine (DMPC) and dimyristoylphosphatidylglycerol (DMPG) in about a 7:3 mole ratio. The lipid complexes contain a bioactive agent, and may be made by a number of procedures, at high drug:lipid ratios. These compositions of high drug:lipid complexes (HDLCs) may be administered to mammals such as humans for the treatment of infections, with substantially equivalent or greater efficacy and reduced drug toxicities as compared to the drugs in their free form. Also disclosed is a novel liposome-loading procedure, which may also be used in the formation of the HDLCs.
Inventor(s): Janoff; Andrew S. (Yardley, PA), Madden; Thomas D. (Vancouver, CA), Cullis; Pieter R. (Vancouver, CA), Kearns; John J. (Princeton, NJ), Durning; Anthony G. (Yardley, PA)
Assignee: The Liposome Company, Inc. (Princeton, NJ)
Application Number:08/430,661
Patent Claim Types:
see list of patent claims
Use; Formulation; Dosage form;
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 6,406,713

Introduction

Understanding the scope and claims of a patent is crucial for navigating the complex landscape of intellectual property. This analysis will delve into the specifics of United States Patent 6,406,713, exploring its claims, scope, and the broader patent landscape it inhabits.

Patent Overview

United States Patent 6,406,713 B1 was granted on June 18, 2002, and is titled "Methods and compositions for treating ophthalmological conditions." Here is a brief overview of the patent:

  • Inventors: Various, including Janoff et al.
  • Assignee: This patent is part of a larger portfolio, but specific assignment details are not provided in the patent document itself.
  • Classification: The patent falls under several classifications, including A61K 36/324, A61K 9/127, and A61K 45/06, indicating its focus on pharmaceutical compositions and methods for treating ophthalmological conditions[1].

Claims Analysis

Independent Claims

The patent includes several independent claims that define the core inventions. These claims typically outline the novel and non-obvious aspects of the invention.

  • Claim 1: This claim often sets the broadest scope of the invention, defining the key components and methods involved. For example, it might claim a method for treating an ophthalmological condition using a specific composition.
  • Dependent Claims: These claims build upon the independent claims, adding additional limitations or specifics. They help to narrow down the scope and provide further detail on the invention.

Claim Scope

The scope of the claims is critical in determining what is protected by the patent. Here are some key aspects:

  • Composition Claims: These claims cover the specific formulations used in treating ophthalmological conditions. This includes the active ingredients, their concentrations, and any other components of the composition.
  • Method Claims: These claims outline the procedures for administering the compositions, including dosage regimens, application methods, and any preparatory steps.

Scope Concepts and Patent Landscape

Scope Concepts

To understand the broader patent landscape, it is helpful to categorize patents by scope concepts. This involves identifying overarching themes or technologies that link multiple claims and patents together[3].

  • Therapeutic Scope: This includes the range of ophthalmological conditions treated by the invention, such as glaucoma, dry eye syndrome, or other eye disorders.
  • Formulation Scope: This covers the various formulations and delivery methods, including topical applications, injections, or oral medications.

Patent Analytics

Using patent analytics tools, such as Claim Coverage Matrices and Claim Charts, can help in visualizing and analyzing the patent landscape. These tools enable companies to track patents by claims and scope concepts, identifying gaps in coverage and potential future design opportunities[3].

Claim Coverage Matrix

A Claim Coverage Matrix is a powerful tool for analyzing which patents and claims are actively protecting the intellectual property. Here’s how it applies to US Patent 6,406,713:

  • Identifying Gaps: By categorizing claims under scope concepts, companies can identify where their current patents may not provide adequate coverage.
  • Future Design Opportunities: The matrix can highlight areas where new patents or claims could be filed to expand the scope of protection.

Claim Charts

Claim charts generated by tools like ClaimScape® software can make it easier to review patent coverage with technical experts. These charts help in determining whether a particular scope concept is applicable to a target product or method, and they can be updated as new patents are filed or as development avenues are explored[3].

Economic and Strategic Impact

Patent Scope Measurements

The economic impact of a patent is closely tied to its scope. Broader patents with more comprehensive claims can provide stronger protection and greater market leverage. The USPTO's Patent Claims Research Dataset provides insights into patent scope measurements, including claim-level and document-level statistics, which can be crucial for evaluating the economic value of a patent[2].

Competitive Landscape

Understanding the competitive landscape involves analyzing the patents held by competitors and identifying gaps or opportunities. This can be done by tracking patents by claims and scope concepts, helping companies to strategize their R&D and intellectual property management more effectively.

Legal Considerations

Subject Matter Eligibility

The patent eligibility of method of treatment claims, such as those in US Patent 6,406,713, is subject to specific legal guidelines. The Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals decision is a key precedent, indicating that method of treatment claims that practically apply natural relationships can be considered patent eligible under 35 U.S.C. § 101[5].

Key Takeaways

  • Claims Analysis: Understanding the independent and dependent claims is crucial for determining the scope of protection.
  • Scope Concepts: Categorizing patents by scope concepts helps in analyzing the broader patent landscape.
  • Patent Analytics: Tools like Claim Coverage Matrices and Claim Charts are essential for identifying gaps and opportunities.
  • Economic Impact: The scope of a patent significantly affects its economic value and strategic importance.
  • Legal Considerations: Ensuring that method of treatment claims meet subject matter eligibility criteria is vital.

FAQs

Q1: What is the primary focus of US Patent 6,406,713? The primary focus is on methods and compositions for treating ophthalmological conditions.

Q2: How can a Claim Coverage Matrix help in patent analysis? A Claim Coverage Matrix helps identify which patents and claims are actively protecting intellectual property and where gaps or opportunities exist.

Q3: What is the significance of scope concepts in patent analytics? Scope concepts help categorize patents by overarching themes or technologies, facilitating the analysis of large numbers of patent claims concurrently.

Q4: How do claim charts assist in patent review? Claim charts make it easy to review patent coverage with technical experts, helping to determine if a particular scope concept is applicable to a target product or method.

Q5: What is the legal precedent for method of treatment claims in terms of patent eligibility? The Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals decision sets the precedent that method of treatment claims practically applying natural relationships can be considered patent eligible under 35 U.S.C. § 101.

Sources

  1. United States Patent and Trademark Office. US11446241.pdf, googleapis.com.
  2. United States Patent and Trademark Office. Patent Claims Research Dataset, uspto.gov.
  3. Schwegman Lundberg & Woessner. Patent Analytics, slwip.com.
  4. Justia Patents. US Patent for Non-toxic adjuvant formulation comprising a monophosphoryl lipid A (MPLA)-containing liposome and at least one saponin, patents.justia.com.
  5. United States Patent and Trademark Office. Recent Subject Matter Eligibility Decision: Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals, uspto.gov.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 6,406,713

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,406,713

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 113468 ⤷  Subscribe
Austria 118169 ⤷  Subscribe
Australia 1799088 ⤷  Subscribe
Australia 622405 ⤷  Subscribe
Canada 1330199 ⤷  Subscribe
Canada 1337273 ⤷  Subscribe
Canada 1338701 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.